Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations

What Was Tested

Researchers studied Peptide YY and Cholecystokinin (CCK) in this controlled clinical trial publication.

However, the effects of Orlistat on the secretion of appetite regulating gastrointestinal hormones and appetite sensations are still debated.

The researchers addressed whether Orlistat alters the secretion of glucagon-like peptide-1-(7-36)-amide (GLP-1), cholecystokinin (CCK), peptide YY (PYY), and ghrelin as well as postprandial appetite sensations.

Who Took Part

PubMed indexes the participants as adults.

Twenty-five healthy human volunteers were examined with a solid-liquid test meal after the oral administration of Orlistat or placebo.

How the Study Was Run

The researchers set it up as a placebo-controlled study.

Some participants received a placebo instead of Peptide YY, giving a reference point.

Gastric emptying, gallbladder volume and the plasma levels of CCK, PYY, GLP-1, and ghrelin were determined and appetite sensations were measured using visual analogue scales.

What Was Measured

However, the effects of Orlistat on the secretion of appetite regulating gastrointestinal hormones and appetite sensations are still debated.

The subject headings attached to it are Appetite, Cholecystokinin, Enzyme Inhibitors, Gastric Emptying, Glucagon-Like Peptide 1, Intestines and Lactones.

What This Means in Plain Language

The paper is a placebo-controlled study of Peptide YY and Cholecystokinin (CCK).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Peptide YY compound page and the Cholecystokinin (CCK) compound page, all human trials.